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Abstract
Type 2 diabetes mellitus (T2DM) progression increases oxidative stress which contributes to
beta cell compensation and eventual dysfunction. To investigate the role of antioxidant Nacetyl-L-cysteine (NAC) on beta cell function and pancreatic stellate cell activation
(SMA+) during early and late stages of compensation, NAC was used for preventative (p)
and intervention (i) treatments in C57BL/6N mice fed a 60% kcal high-fat diet (HFD) for 8
or 22 weeks. Significantly improved glucose tolerance was observed at 22 weeks following
pNAC treatment in HFD mice. Although 22-week HFD mice displayed hyperinsulinemia,
beta cell hypertrophy, decreased beta cell PDX-1 nuclear localization, and increased intraislet SMA+ cells, HFD mice with iNAC treatment normalized beta cell mass and insulin
secretion, improved nuclear PDX-1 labeling, and decreased intra- islet SMA+ staining. In
conclusion, NAC treatment prevented beta cell over-compensation associated dysfunction
and improved metabolic outcomes in diet-induced obesity T2DM mouse models.

Keywords: Type 2 diabetes, oxidative stress, beta cell, N-acetyl-L-cysteine, pancreatic
stellate cell, high-fat diet
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Summary for Lay Audience
Type 2 diabetes mellitus (T2DM) is a progressive disease that occurs in multiple stages, with
each stage causing increased levels of stress on cells responsible for lowering blood sugar
through the hormone insulin. Early in T2DM, the body requires more insulin production.
Insulin-producing cells can keep up with this demand for a short period of time by increasing
their size and number. However, the increased demand for insulin causes insulin-producing
cells to develop complications, which eventually leads to their failure. The drug N-acetyl-Lcysteine (NAC) has been shown to decrease a type of stress found in T2DM insulinproducing cells. This study determined whether decreasing the stress using NAC could help
protect the insulin-producing cells, and when it was most effective. When NAC was given to
mice that demonstrated T2DM progression, their insulin-producing cells were partially
protected from developing dysfunction when compared to insulin-producing cells from
T2DM mice not treated with NAC. These cells increased markers of their ability to produce
and release insulin, did not increase in size, and did not overproduce insulin, suggesting they
were functioning more like the normal insulin-producing cells rather than those experiencing
T2DM. However, no significant improvement was found in overall blood sugar levels from
T2DM mice treated with NAC. When NAC was given to mice one week before T2DM
started, significant improvements in blood sugar levels and improvements in the size of the
insulin-producing cell area were found. In conclusion, NAC may be able to protect insulinproducing cells from the dysfunction associated with overcompensation during T2DM, as
well as whole-body metabolic changes when taken early enough and for a long-time
duration.
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Chapter 1

1

Introduction

1.1 Significance of the Study
Type 2 diabetes mellitus (T2DM) is a complex disease with multiple stages of
progression, involving intrinsic compensatory mechanisms as well as dysfunctional overexertion of the beta cells. During the progression of T2DM, levels of oxidative stress
increase and can cause direct damage to both islets and peripheral tissues. Short- and
long-term antioxidant treatment of T2DM with N-acetyl-L-cysteine (NAC) has been
found to reduce oxidative stress levels in peripheral tissue and improve insulin resistance
and glucose tolerance in diet-induced obesity (DIO) rodent models of T2DM. However,
short-term NAC administration has not demonstrated efficacy in diabetic patients. This
has led to the hypothesis that NAC treatment efficacy may be dependent on the timepoint and duration of its administration. While the effects of NAC on peripheral tissues
have been extensively reported, its effects on beta cell function in vivo are still not well
understood. This work examines the impact of NAC administration at different time
points in a DIO rodent model on beta cell compensation and dysfunction.

1.2 Overview of the Pancreas and the Islets of Langerhans
Unlike the human pancreas, which has a defined shape, the rodent pancreas is a diffuse
organ that stretches horizontally between the duodenum and spleen before continuing to
the mesentery surrounding the duodenum (Dolenšek et al., 2015). The exocrine pancreas
accounts for approximately 96% of total pancreas volume (Dolenšek et al., 2015) and is
responsible for the production and secretion of digestive enzymes through the pancreatic
duct to the duodenum (Campbell-Thompson, Rodriguez-Calvo, & Battaglia, 2015). The
islets of Langerhans, which compose only 1-2% of the total pancreas volume, contain
endocrine cells that produce multiple hormones involved in maintaining glucose
homeostasis. There are five main cell types within the islets: alpha, beta, delta, gamma,
and epsilon cells that produce glucagon, insulin, somatostatin, pancreatic polypeptide,
and ghrelin, respectively (Campbell-Thompson et al., 2015). The most abundant

2

endocrine cell type in the rodent islet is the beta cell (60-80%), found within the core of
the islet, followed by the alpha cells located on the periphery (10-20%). In contrast,
human islets contain a more scattered distribution of beta and alpha cells throughout the
islet, with a slightly lower beta to alpha cell ratio (Dolenšek et al., 2015).

1.3 Beta Cell Identity and Function
To properly respond to increased blood glucose levels, beta cells must maintain mature
beta cell identity through active regulation of gene expression using transcription factors
such as pancreatic and duodenal homeobox-1 (PDX-1). In beta cells, nuclear PDX-1 is
involved in sensing and responding to high glucose environments by up-regulating
insulin transcription (Ahlgren et al., 1998; Kaneto et al., 2015). Once the islets have
reached maturity, beta cells have very low proliferation rates and an average mass of
about 1 mg (Chintinne et al., 2012). Alterations in levels of transcription factors, proteins
responsible for insulin release, proliferation rates, and beta cell mass can all be found
during the progression of islet pathology during T2DM.
In response to a post-prandial blood glucose, the beta cells release insulin in two phases.
Circulating glucose enters the beta cell and triggers membrane depolarization and an
influx of Ca2+ ions, beginning release of insulin into the blood stream. During phase one
of biphasic insulin release, insulin-containing vesicles that are pre-docked to the plasma
membrane through SNARE protein complex formation between the vesical and the
plasma membrane (Hou et al., 2009), the readily releasable pool of granules, undergo
exocytosis. Following this short and rapid burst of insulin release, phase two insulin
granules from the reserve pool translocate to the same plasma membrane release sites for
exocytosis (Henquin et al., 2002). Insulin release allows for GLUT4-mediated glucose
uptake into adipose tissue and skeletal muscle for energy use and storage (Rossmeisl et
al., 2003) as well as suppresses liver metabolism of glycogen, allowing the body to
return to normoglycemia (Hou et al., 2009; Straub & Sharp, 2002). While beta cells are
known to respond during hyperglycemic conditions, under physiological conditions alpha
cells respond to hypoglycemia by releasing glucagon in order to raise blood glucose
levels. This results in stimulation of the liver to break down glycogen into glucose to
maintain normoglycemia (Titchenell et al., 2017).
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1.4 Diabetes Mellitus in Humans
The two major types of diabetes mellitus are distinguished based on the etiology that
ultimately leads to beta cell failure. Type 1 diabetes mellitus (T1DM) is an autoimmune
disorder where the body targets insulin-secreting beta cells and induces cell death,
leading to insufficient insulin production (Kosiewicz et al., 2019). Due to the severity of
beta cell loss, exogenous insulin is required to avoid hyperglycemia. T2DM is a
multifactorial disease that progresses through a series of stages that include whole body
and pancreatic alterations (Figure 1.1). Stage progression during T2DM in humans does
not always occur in a strictly linear fashion, but typically begins with a shift from a
metabolically healthy to a prediabetic state that is often facilitated by obesity (Keane et
al., 2015; McAdam-Marx et al., 2014). The prediabetic state is characterized by
hyperinsulinemia and insulin resistance in peripheral tissues (Yang et al., 2016), where
insulin receptor signaling that allows glucose uptake and storage no longer properly
responds to insulin signaling. Prediabetes includes a compensatory mechanism where
beta cells increase insulin output to overcome reduced insulin receptor sensitivity and
achieve normoglycemia (Butler et al., 2003; Prentki & Nolan, 2006). The progression to
later stages of T2DM depends on multiple influences, including environmental and
genetic factors. Glycemic control is no longer observed during full T2DM (Wu et al.,
2014).
Early treatments for T2DM may include lifestyle changes, such as diet and exercise. In
cases where medication is necessary, the most commonly prescribed treatments decrease
liver gluconeogenesis and increase peripheral tissue glucose uptake (metformin) or
increase beta cell insulin release (DPP-4 inhibitors or sulfonylureas). In severe cases of
beta cell dysfunction, exogenous insulin may be required (Marín-Peñalver et al., 2016).
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Legend:

Figure 1.1: T2DM progression in peripheral tissue and islet morphology. In a nondiabetic individual, insulin binds to insulin receptor to allow for GLUT4 -regulated
glucose uptake on skeletal muscle and adipose tissue and suppression of glycogen
production in the liver. Islets at this time have unaltered beta cell activity and no
intervention is required with the maintenance of healthy eating and lifestyle patterns. In
the pre-diabetic stage of T2DM progression, oxidative stress levels increase due to
insulin resistance. Due to the tissue’s inability to respond to insulin, an increased demand
is placed on the beta cells that then induces increased size and/or number, leading to
hyperinsulinemic levels that are able to maintain normoglycemia. Treatment at this timepoint includes improving diet and exercise but may progress to requiring metformin. In
later stages of T2DM, the beta cells can no longer keep up with the high insulin demand
and results in beta cell dysfunction and hyperglycemic conditions. Treatments of latestage T2DM patients involves drugs such as metformin or sulfonylureas, but exogenous
insulin may be required if beta cell dysfunction is extensive. Figure created with
BioRender.
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1.5 Diabetic Animal Models for T2DM Research
Diabetic animal models have played an important role in elucidating the specific nature
of insulin regulation, secretory defects, and limitations of beta cell growth to provide a
better understanding of T2DM and its associated complications. It has been found that
high-fat diet (HFD) induced T2DM progression in C57 black 6 (C57BL/6) mice is
similar to the progression found in humans as the C57BL/6J and C57BL/6N mouse lines
are susceptible to HFD-induced weight gain, hyperinsulinemia, and hyperglycemia
(Nicholson et al., 2010). In another rodent model of T2DM, the Sprague-Dawley rat,
increased levels of systemic reactive oxygen species (ROS) accumulation caused by
increased intake of free fatty acids (FFAs), lipid peroxidation, and decreased antioxidant
status, lead to the development of oxidative stress (Zhang et al., 2010). As over nutrition
and oxidative stress progress, the beta cell compartment is unable to maintain normal
regulation and beta cell identity (Ježek et al., 2019). Beta cells in this stage begin
compensatory measures to attempt to re-establish normoglycemia.
While C57BL/6J (B6J) is a very common strain used in DIO T2DM modelling,
C57BL/6N (B6N) is also highly susceptible to 60% HFD and possess a slightly different
genetic background and presentation of T2DM (Nicholson et al., 2010). B6N strain of
mouse was derived from the same parent strain of C57BL/6 mice as B6J mice, however,
B6N mice have been known to display a slightly milder phenotype of T2DM (Fontaine &
Davis, 2016). Interestingly, while B6J mice display the more severe phenotype, reduced
insulin secretion is found to be independent of changes in beta cell mass or insulin
sensitivity in lean mice, suggesting an insulin secretion defect in the B6J sub strain likely
related to the nicotinamide nucleotide transhydrogenase (Nnt) allele mutation found in
B6J, but not B6N, mice (Aston-Mourney et al., 2007; Fergusson et al., 2014). The Nnt
allele encodes a mitochondrial enzyme for Nnt, a part of a proton pump responsible for
nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) generation (AstonMourney et al., 2007). Possession of the wild-type Nnt allele may make the B6N strain
more comparable to the human condition as it is present within human mitochondria
(Fisher-Wellman et al., 2016). Additionally, less genetic variability has been found
between mice of the B6N sub strain compared to B6J mice (Mekada et al., 2009), which
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combined with the lack of potential compensatory mechanisms found in B6J mice
associated with loss of Nnt function, has led to the suggestion that B6N mice may be a
better representation of metabolic disorder (Fisher-Wellman et al., 2016).

1.6 Beta Cell Compensation in T2DM
As over-nutrition induces peripheral insulin resistance and impaired glucose tolerance
(Rani et al., 2016), the beta cells respond to the increased insulin demand and stress
signaling by initiating hypertrophy (Cox et al., 2016) and increasing proliferation rates
(Mosser et al., 2015). These beta cells enter a compensatory phase of insulin secretion
and display an increase in nuclear FOXO1 staining, which has been associated with
increased insulin secretion (Zhang et al., 2016). However, while the increase in nuclear
FOXO1 has been shown to be necessary for increased insulin release during metabolic
stress, it can also induce beta cell dysfunction and reduced beta cell mass (Kobayashi et
al., 2012). As beta cell compensation progresses towards dysfunction, they display
reduced nuclear PDX-1 staining due to high levels of oxidative stress (Kawamori et al.,
2003) In addition to the beta cell-specific changes, prolonged HFD-induced
compensation affects the islet microenvironment by increasing collagen deposition and
intra-islet pancreatic stellate cell activation (PaSC) (Lee et al., 2017). Eventually, the beta
cells are no longer able to compensate and a decrease in functional beta cell mass is
observed due to dysfunction and loss of mature beta cell identity related to chronic
oxidative stress and glucotoxicity (Prentki & Nolan, 2006; Swisa et al., 2017).

1.7 Pancreatic Stellate Cells in T2DM
The PaSC is a mesenchymal-like cell type located throughout the periacinar regions of
the pancreas and within the pancreatic islets (Zha et al.,2014), constituting about 4% of
all pancreatic cells (Apte et al., 1998). The majority of PaSCs are quiescent under
physiological conditions and are primarily responsible for extracellular matrix turnover
via the balanced production of matrix metalloproteinases (MMPs) and tissue inhibitors of
matrix metalloproteinases (TIMPS) (Xue et al., 2018). PaSC activation occurs with ROS
accumulation, mechanical stress, or cytokine activation, causing these cells to take on a
myofibroblast phenotype. Once active, PaSCs express alpha smooth muscle actin
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(αSMA) and increase their production of collagen I, platelet derived growth factor,
transforming growth factor beta, interleukin 1-beta, and various other inflammatory
cytokines and fibrosing responses that can be harmful to the islets (Hayden et al., 2007;
Masamune et al.,2009).
Active PaSCs have been identified as major contributors to fibrosis in the course of
various pancreatic pathologies, including pancreatitis and pancreatic cancer, due to their
dysfunctional MMP/TIMP balance and increased collagen deposition. They are also
reported to play a role in up-regulating the epithelial-mesenchymal transition of
pancreatic cancer cells, allowing for their increased ability to metastasize (Pandol &
Edderkaoui, 2015). In addition to their support of tumor metastasis, PaSCs have been
shown to promote inflammation within the islets, both through increased secretion of
cytokines as well as interaction with inflammatory cells, promoting increased
macrophage infiltration (Pandol & Edderkaoui, 2015; Saito et al., 2012).
Recent evidence has demonstrated that active PaSCs can contribute to factors involved in
the progression of T2DM (Figure 1.2). Hyperinsulinemia and hyperglycemia are able to
increase oxidative stress, contributing to beta cell dysfunction. It has been shown that
high levels of insulin and glucose are also found to have both independent and additive
effects on the activation and proliferation of PaSCs (Hong et al., 2007). The activation of
PaSCs under hyperglycemic and hyperinsulinemic stresses were found to be related to
increased levels of oxidative stress in PaSCs (Ryu et al., 2013). Active PaSCs are able to
increase levels of insulin when co-cultured with beta cells for a short time period.
However, due to a potential lack of insulin replenishment (Zang et al., 2015), co-culture
contributes to long term beta cell dysfunction and decreased insulin response over
multiple days, and is associated with beta cell dysfunction and apoptosis (Kikuta et al.,
2013; Zang et al., 2015).
Due to negative impacts found following activation of PaSCs, methods of reducing PaSC
activation have been investigated. When activated by the culture process due to
mechanical stress and ROS accumulation, PaSCs can be returned to a quiescent
phenotype using Matrigel as well as NAC (Jesnowski et al., 2005). Using plant alkaloid
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conophylline to reduce intra-islet PaSC activation in Goto-Kakizaki (GK) rats, a
reduction in islet fibrosis and an increase in pancreas insulin content were noted (Saito et
al., 2012). However, whether a definitive relationship exists between PaSC activation and
beta cell dysfunction has not yet been established (Lee et al., 2017), and whether shortterm activation of PaSCs plays a role in increasing beta cell compensation has yet to be
determined.
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Figure 1.2: PaSC activation and proposed interaction with beta cells
PaSCs exist in the physiological islet in a quiescent state, where they primarily regulate
ECM turnover through the production of MMPs and TIMPs. Following their activation,
quiescent PaSCs lose their vitamin A droplets and become αSMA+ myofibroblast-like
cells (left figure). Active PaSCs then produce growth factors, cytokines, and ECM
components that may contribute to beta cell growth during compensation (middle figure).
However, PaSCs are able to maintain long-term activation through autocrine and
paracrine loops and could potentially become over-active, resulting in the overproduction of ECM components and inflammatory cytokines (right figure). This overproduction from PaSCs could lead to the islet fibrosis and inflammation found in T2DM
and contribute to eventual beta cell dysfunction. Figure created with BioRender.
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1.8 Oxidative Stress in T2DM
An imbalance between reactive oxygen species (ROS) and antioxidants in T2DM patients
leads to an increase in oxidative stress. These ROS are mainly believed to be produced by
the mitochondria in response to increased glucose and are normally reduced via
intracellular antioxidants such as glutathione to a less harmful species (Sies, 2017).
However, plasma samples from T2DM patients show increased lipid peroxides and
reactive oxygen metabolites compared to non-diabetic controls, which is associated with
significantly lower glutathione (GSH) levels (Sekhar et al., 2011). GSH is a tripeptide
made up of glutamate, cysteine, and glycine, and functions as a major ROS scavenger in
both human and rodent systems. While most mammalian cells can synthesize GSH, it is
mainly produced and released by hepatocytes (Wu et al., 2004). Low GSH levels are
caused by oxidation of GSH to become glutathione disulfide (GSSG) in conditions with
increased levels of ROS, leading to a reduced GSH/GSSG ratio which cannot be naturally
rectified through compensation with increased GSH synthesis, a problem commonly
attributed to lack of precursor limited availability of precursors such as cysteine (Fujii et
al.,

2011; Sekhar et al., 2011). When deficient, GSH itself cannot be effectively

replenished through oral administration due to the metabolic action of γglutamyltransferase, a transferase capable of hydrolyzing GSH in the intestine (Cohen et
al., 1969; Springer-Verlag et al., 1992). Lack of GSH formation may be partially
attributed to the low cysteine levels found in the blood of T2DM patients compared to
non-diabetic controls. However, cysteine is non-polar and has poor intestinal absorption
levels paired with rapid hepatic metabolism, making oral cysteine administration another
poor option for increasing cysteine levels.
In order to increase cysteine and GSH levels, an acetyl group is added to cysteine to
create NAC, most of which can be absorbed through the intestinal wall. Following oral
ingestion and intestinal absorption, NAC undergoes extensive first pass metabolism by
the liver that greatly reduces its bioavailability (Lasram et al., 2015). NAC deacetylates
in the blood of the hepatic portal vein and L-cysteine enters the hepatocytes to become
GSH (Tran et al., 2004). GSH is then able to function as a reactive oxygen species
scavenger (Figure 1.2).
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Figure 1.3: The direct and indirect mechanisms of NAC antioxidant action
Following intake through the drinking water, NAC is known to have either an indirect or
direct mechanisms of antioxidant action. The indirect method is thought to be the
predominant method, wherein NAC is deacetylated to become L-cysteine and proceeds to
enter the liver. L-cysteine then binds to L-glutamate during an adenosine-triphosphate
(ATP)-dependent reaction catalyzed by glutamyl cysteine ligase to become γglutamlycysteine. Glycine is then required to join γ-glutamlycysteine through another
ATP-dependent reaction reliant on the glutathione synthetase enzyme to ultimately create
GSH. GSH is then able to act as a ROS scavenger. Alternatively, NAC can act as a direct
ROS scavenger due to the ability of its thiol group to donate electrons to reactive oxygen
species. Figure created with BioRender.
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1.9 Research on Antioxidant Therapies for T2DM
Due to the evidence of rising levels of oxidative stress and decreased levels of intrinsic
antioxidants in T2DM patients, antioxidant therapies are often studied in T2DM research
models. Various strategies have been attempted, including enzymatic antioxidants
(Glutathione peroxidase mimetics), antioxidant vitamins (Vitamin C), and non-vitamin
antioxidants (Coenzyme Q10, NAC) (Table 1.1) (Rochette et al., 2014). However, while
antioxidants have been studied in various rodent models, NAC has shown efficacy in
improving metabolic outcomes in DIO models of the disease, which closely resemble
human progression of T2DM (Shen et al., 2019). NAC has also proven to be useful in
improving insulin sensitivity in human patients with polycystic ovary syndrome
(Dasgupta et al., 2015).
NAC is well known as a biosynthetic precursor to GSH, as the ability of NAC to increase
levels of GSH is an indirect antioxidant effect and is reported to be its main mechanism
of antioxidant action (Ma et al., 2016). However, NAC also contains a thiol group that
can donate electrons to unstable ROS elements such as hydrogen peroxide, which then
exerts direct antioxidant effects (Lasram et al., 2015). Due to its abilities as an
antioxidant as well as a mucolytic agent, NAC is currently used in the clinical setting as a
treatment or adjuvant treatment of various pathologies, some of which include
acetaminophen overdose, chronic obstructive pulmonary disease, clomiphene citrate
resistant polycystic ovary syndrome, chronic bronchitis, and liver cancer (Dekhuijzen,
2004; Lasram et al., 2015; Mokhtari et al., 2017).
NAC administration through drinking water has been shown to improve metabolic
outcomes in DIO rodent models of T2DM. Specifically, improved glucose tolerance is
found to be linked to increased insulin sensitivity following NAC administration. This
increase in insulin sensitivity was associated with decreased fat accumulation in the liver
(Falach-Malik et al., 2016) and decreased accumulation of visceral fat (Shen et al., 2019).
While the decrease in fat accumulation was not found to be due to reduced caloric intake,
which was unchanged in NAC treated rodents when compared to control litter-mates
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(Falach-Malik et al., 2016; Novelli et al., 2009; Shen et al., 2019), this significant change
in body weight may be connected to increased motor activity that enhances resting
metabolic rates as well as fat oxidation (Novelli et al., 2009; Shen et al., 2019).
In vitro models of cultured islets treated with NAC have shown that the antioxidant is
capable of reducing levels of oxidative stress, predominantly related to the presence of
H2O2. When administered to pancreatic islets isolated from Wistar Rats and treated with
dexamethasone, a corticosteroid associated with the ability to increase levels of oxidative
stress related to increased levels of H2O2 (Roma et al., 2013; Tome et al., 2011), NAC
was able to improve beta cell insulin release following stimulatory concentrations of
glucose compared to islets treated with only dexamethasone (Roma et al., 2013).
Additionally, it has been shown that increasing ribose levels in islets cultured from
Wistar rats increased oxidative stress, which was improved by NAC administration.
(Tanaka et al., 2002).
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Table 1.1. Antioxidant subgroups used in models of T2DM
Drug Name,
Type

Ebselen,
Glutathione
Peroxidase
Mimetic

Antioxidant
Function

Catalyzes
reduction of
H2O2 to H2O

Efficacy in Rodent
Model
of T2DM
•Improve
hyperinsulinemia,
hyperglycemia, nuclear
PDX-1 in beta cells,
decrease beta cell
apoptosis in Zucker
diabetic fatty rat

Efficacy in Human
Study of T2DM
•No improvement in
levels of oxidative stress
(Beckman et al., 2016)

(Mahadevan et al., 2013)

Vitamin C,
Antioxidant

Electron
Donor

Vitamin

Coenzyme
Q10,
Non-vitamin
Antioxidant

NAC,
Non-vitamin
Antioxidant

•Mice able to compensate
for vitamin C deficiency
via hepatic de novo
biosynthesis. Obesity
linked to deficiency in
humans.

•May improve glucose
concentration in T2DM
patients with higher
BMI’s when administered
for <30 days
(Ashor et al., 2017)

(Tranberg et al., 2014)

Scavenge free
lipid radicals,
ROS in cellular
membrane

Glutathione
Precursor

•Prevent lipid
accumulation in B6J DIO
non-alcoholic fatty liver
disease model

•Improves glycemic
control in patients with
metabolic syndrome but
not in T2DM patients

(Frei et al., 1990; Chen et al.,
2019)

(Suksomboon et al., 2015;
Raygan et al., 2016)

•Improve
hyperinsulinemia,
hyperglycemia in DIO
B6J mouse model

•Lack of improvement on
markers of glucose
metabolism following
short-term NAC treatment

(Falach-Malik et al., 2016;
Shen et al., 2019)

(Szkudlinska et al., 2016)

•Improves insulin
sensitivity in PCOS
patients
(Dasgupta et al., 2015)
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1.10 Project Purpose and Outline
Previous research has demonstrated that NAC treatment in rodents improved glucose
tolerance and insulin sensitivity, and that the efficacy of NAC to induce this improvement
is dependent on the treatment dosage (Falach-Malik et al., 2016). NAC has also been
shown to decrease levels of oxidative stress in pancreatic islets in vitro (Roma et al.,
2013; Tanaka et al., 2002) and has been able to improve glucose tolerance in mice
(Falach-Malik et al., 2016; Shen et al., 2019). However, clinical trials on T2DM patients
have found that NAC treatments are not effective (Szkudlinska, Von Frankenberg, &
Utzschneider, 2016). While NAC has demonstrated different levels of efficacy depending
on length of administration, whether NAC is effective as a preventative treatment in
short- or long-term studies has yet to be determined in rodents. In addition, no study to
date has examined the effects of duration-dependent NAC treatments on beta cell
function during the progression of T2DM. For this thesis, I studied the effects of NAC
administration on glucose tolerance and beta cell compensation in a DIO mouse model
during short-term (8 weeks) and long-term (22 weeks) prevention treatments as well as
during NAC intervention (at 12 weeks of a 22-week HFD) treatment.

16

Objective:
To assess the effects of NAC on glucose tolerance and beta cell compensation when
administered as a preventative or as an intervention treatment during HFD-induced
T2DM progression in mice.

Hypothesis:
Prevention or intervention treatment using NAC during HFD-associated beta cell stress
will improve glucose tolerance, beta cell function, and the expression of activated intraislet (αSMA+) PaSCs in mice.

Specific Questions:
1. What duration of HFD is required to induce glucose intolerance and insulin resistance?
2. Does administration of NAC prior to the beginning of HFD prevent glucose
intolerance in mice?
3. Does preventative NAC administration enhance beta cell mass during early
compensation in HFD mice?
4. Is preventative NAC treatment able to inhibit the intra-islet activation of PaSCs in
vivo?
5. Does administration of NAC during HFD improve glucose tolerance in mice?
6. Does administration of NAC during HFD prevent later stage beta cell failure
associated with T2DM progression?
7. Is intervention NAC treatment able to reduce PaSC activation during HFD in vivo?
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Chapter 2

2

Research Design and Methods

2.1 Mouse colony maintenance and experimental design
for NAC treatments
Male C57BL/6N (B6N) mice purchased from Charles River (Charles River Laboratories
Quebec, Canada) were bred and housed in our facility with a maximum of 5 mice per
cage. At 6-weeks of age, mice received either a normal chow diet (ND) composed of
22% kcal from fat, 23% kcal from protein and 55% kcal from carbohydrates (Harlan
Tekard, Indianapolis, IN, USA) or a high-fat diet (HFD) composed of 60% kcal from fat,
20% kcal from protein and 20% kcal from carbohydrates (Research Diets INC, New
Brunswick, NJ, USA) ad libitum. Mice received either a ND or HFD for a short term 8week or a 22-week long term feeding period (Figure 2a).
Antioxidant treatment with N-acetyl-L-cysteine (NAC) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) was administered to both ND and HFD groups either in a
prevention (pNAC) or intervention (iNAC) treatment. For pNAC treatment, mice
received NAC 1 week prior to HFD and treated through 8-week (pNAC-HFD8) or 22week (pNAC-HFD22) periods (Figure 2b). For iNAC treatment, mice received NAC at
week 12 of HFD and continued NAC intake for the duration of the 22-week HFD (iNACHFD) (Figure 2b). ND controls were treated in parallel. Initially two NAC dosages at 10
and 50mM were tested (Falach-Malik et al., 2016; Shen et al., 2019). The 50mM dosage
was determined to be an effective treatment so this study focused on using 50mM NAC
in drinking water for all antioxidant treatment groups. NAC-supplemented drinking water
was replaced weekly. NAC intake was assessed in each antioxidant treatment group (over
a three-day period) by measuring the difference in volume of water placed in the cage at
the beginning of the three-day period compared to the end. This was done two to three
weeks after beginning NAC treatment and at the end of each experimental treatment.
Data are expressed as NAC intake mg per mouse per day (Shen et al., 2019).
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All mice were maintained on a 12-hour light/12-hour dark cycle. Weekly body weights
were monitored for all groups, food intake was measured over 16 hours at the end of the
assigned diet period in each cage by measuring the change in food weight. Total food
intake for the cage was multiplied by kilocalories per gram of food (3.3 kcal/g for ND
and 5.21 kcal/g for HFD) and divided by total body weight of mice in the cage to get
kcal/g of mouse. Kcal/g of mouse was then multiplied by the body weight of each
individual mouse in the cage to get kcal/mouse/16hrs. This was then used to calculate
kcal/mouse/24 hours. Food intake is expressed as kcal per mouse per day. All animal
work was conducted based on approved protocols from the University of Western
Ontario Animal User Subcommittee in accordance with the Canadian Council of Animal
Care guidelines (Appendix A).
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A

B
B

Figure 2.1: Timeline for diet and NAC treatments in intervention and prevention
mouse studies.
(A) Male C57Bl/6N mice were fed a 60% kcal HFD for either a short- (8 weeks) or long(22-weeks) term to assess the progression of glucose and insulin intolerance in mice.
Normal diet (ND) controls were treated in parallel. (B) Mice were treated using
antioxidant NAC for 1-week before a short term or long term HFD feeding period as
prevention treatment (pNAC) or received NAC as an intervention at week 12 of a 22week HFD (iNAC). ND mice were treated in parallel.
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2.2 In vivo metabolic experiments
An intraperitoneal glucose tolerance test (IPGTT) was performed in all experimental
groups at 8 or 22 weeks on the assigned treatments. IPGTT was conducted following a
16-hour overnight fast with a 2mg/g bodyweight glucose administration (Dextrose,
Sigma, Saint Louis, MO, USA). Glucose levels were measured at baseline (0 minutes)
before a glucose injection and at 15-, 30-, 60-, and 120-minutes post-glucose injection
using a glucometer (Freestyle Lite, Abbott, Alameda, California, USA). Differences
between control and experimental groups were compared using area under the curve
(AUC) analyses (Zhi Chao Feng et al., 2015).
An intraperitoneal insulin tolerance test (IPITT) was performed after mice were fasted for
4 hours. 1U/kg bodyweight of insulin (Humulin, Eli Lilly, Toronto, ON, Canada) was
administered to mice on the 22-week diet groups, while 0.75 U/kg bodyweight of insulin
was administered to the 8-week diet groups. Glucose levels were taken at baseline (0
minutes), and at 15-, 30-, 60- and 120-minute following post-insulin administration.
Results were normalized to baseline glucose levels (100%) and AUC values were
generated to determine changes in insulin sensitivity. (Zhi Chao Feng et al., 2015).

2.3 ELISA measurements of insulin secretion
The ultrasensitive insulin mouse ELISA kit from ALPCO (Salem, NH, USA) with
sensitivity at 0.15ng per ml was used to measure insulin levels from fed cardiac blood
plasma in all 22-week diet-only, pNAC and iNAC 22-week 50mM NAC treated groups.
Plasma samples were assayed undiluted and all values were reported as ng/ml.

2.4 Tissue collection and immunohistological analysis
Mice were sacrificed following 8 or 22 weeks of their assigned diet. Immediately
following CO2 euthanasia, cardiac blood samples, pancreata, and livers were collected.
Pancreas weight was also measured at the time of dissection. Pancreas and liver samples
were washed with saline before overnight fixation in 4% paraformaldehyde (Fisher
Scientific Company, Ottawa, ON, Canada). Tissue samples were processed by a standard
protocol of dehydration and paraffin embedding using an automated tissue processing
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and embedding machine (Shandon Citadel™ Tissue Processor, Citadel 1000, Thermo
Electron Corporation, Waltham, MA, USA). Parrafin blocks were sectioned
consecutively at 4-µm with a microtome (Leica RM2245, Vashaw Scientific Inc.;
Norcross, Atlanta, USA) throughout the length of the pancreas.
For immunofluorescence (IF) staining, paraffin sections were deparaffinized in xylene,
rehydrated with decreasing concentrations of ethanol (from 100% to 70%) and rinsed
with running water and 1x phosphate-buffered saline (PBS). Nonspecific binding was
blocked using 10% normal goat serum diluted in 1x PBS at room temperature for 30
minutes in a humidified chamber. Sections were incubated with the appropriate dilutions
of primary antibodies as listed in Table 1 overnight at 4oC. As required, 0.2% Triton
treatment and/or microwave antigen retrieval with citric acid solution (pH 6.0) were
applied to improve detection. Secondary antibodies fluorescein isothiocyanate (FITC)
and tetramethyl rhodamine isothiocyanate (TRITC) secondary antibodies (Jackson
Immunoresearch, West Grove, PA, USA) were applied for primary detection at 1:50
dilution. 4’-6’-diamidino-2-phenylindole (DAPI) was applied for nuclear counterstaining
(1:1000 dilution). Negative controls included the omission of the primary or secondary
antibodies; these tests resulted in negative staining reactions, with some background
staining when mouse derived FITC was used on mouse tissue (Appendix D).
Images of sections were captured by a Leica DMIRE2 fluorescent microscope (Leica
Microsystems, Concord, Ontario, CA). Analysis of islet structure and beta-cell markers
was conducted using Image Pro Plus software (Media Cybernetics, Rockville, MD,
USA). For SMA staining, images were obtained using the Nikon Eclipse Ti2 confocal
microscope (Nikon, Melville, NY, USA) and quantified using Nikon NIS-Elements
software (Nikon, Melville, NY, USA).
Picrosirius Red staining for collagen detection was applied to pancreas and liver samples
using the protocol included with the Picro Sirius Red Kit (Connective Tissue Stain)
(Abcam, Cambridge, MA, USA).
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2.5 Morphometric analysis
Islet morphology was assessed with insulin and glucagon co-staining sections. An islet
was defined as three insulin-positive cells and one glucagon-positive cell. All islets in
each section were counted and divided by pancreas area to calculate islet density
expressed as islet number per square millimeter of pancreatic section (islet#/mm2). Alpha
and beta cell mass was calculated using the following formula: Alpha or Beta cell mass =
[Glucagon-positive area or insulin-positive area x pancreas mass (mg)]/ Pancreatic area
(mm2) (Wang et al., 1994). Beta cell size was calculated by dividing the total insulinpositive islet area by the number of insulin-positive cells in ten representative islets per
section, while beta cell number was calculated by dividing the number of insulin-positive
cells by insulin-positive area in ten representative islets.
Quantification of proliferation (Ki67) and nuclear transcription factors PDX-1 was
accomplished through double IF staining with insulin. Double positive cells (Nuclear
marker-positive/insulin-positive) were divided by the total insulin-positive cell
population in islets and expressed as a percentage (Feng et al., 2012). To quantify the
percentage of activated PaSC marker αSMA present in the islets, the positive intra-islet
αSMA+ cell area (µm2) was manually traced using Nikon NIS-Element software and
divided by the total insulin-positive area (µm2) (Lee et al., 2017).

2.6 Statistical Analysis
ND and HFD groups were compared initially using an unpaired student’s t-test to
establish the model. All diet groups with or without NAC treated were compared using
one-way ANOVA in GraphPad Prism 5.0 followed by Tukey’s Post-Hoc test (GraphPad
Software, Inc., La Jolla, CA, USA). All data is expressed as means ± SEM and statistical
significance was obtained when p<0.05.
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Table 2.1. List of Antibodies Used for Immunofluorescence (IF) Staining Analyses
Primary Antibody

Catalogue

Dilution

Company

Number
Mouse Anti-αSMAƚ

Ab7817

1:100

Abcam (Cambridge, MA, USA)

Rabbit Anti-Glucagon

Sab4501137

1:100

Sigma-Aldrich (St Louis, MO,
USA)

Rabbit Anti-Insulin

Sc-9168

1:50

Santa Cruz (Santa Cruz, CA, USA)

Mouse Anti-Insulin

I2018

1:800

Sigma-Aldrich (St Louis, MO,
USA)

Rabbit Anti-Insulin

C27c9

1:400

Cell Signaling (Temecula, CA,
USA)

Rabbit Anti-Ki67*

Ab15580-100

1:100

Abcam (Cambridge, MA, USA)

Rabbit Anti-Pdx-1*

Gift

1:800

Dr. Christopher V. Wright
(University of Vanderbilt,
Nashville, TN, USA)

Secondary
Antibodies
FITC Goat anti-mouse

115095062

1:50

JRL (West Grove, PA, USA)

FITC Goat anti-rabbit

111095045

1:50

JRL (West Grove, PA, USA)

TRITC Goat anti-mouse

115025062

1:50

JRL (West Grove, PA, USA)

TRITC Goat anti-rabbit

111025045

1:50

JRL (West Grove, PA, USA)

* Indicates microwave antigen retrieval was required; ƚ indicates 0.2% triton treatment
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3

Results

3.1 HFD induced a progressive metabolic dysfunction
mouse model of T2DM
In order to establish when glucose and insulin intolerance appeared during diet-induced
T2DM progression in 6-week old male B6 mice fed a 60% kcal HFD for an 8-week or
22-week period. After an 8-week dietary treatment, HFD mice exhibited significantly
increased body weight (Figure 3.1a) and higher fasted blood glucose levels (Figure 3.1b)
compared to the ND group. Significantly impaired glucose tolerance (Figure 3.1c), but
not insulin tolerance (Figure 3.1d), was observed in 8-week HFD mice, suggesting that
insulin resistance has not yet developed in HFD mice during this period.
After 22 weeks of diet treatment, HFD mice showed an increase in both final body
weight (Figure 3.2a) and fasted blood glucose levels (Figure 3.2b) compared to ND
controls. These mice also demonstrated increased non-fasted plasma insulin levels
(Figure 3.2c). Both impaired glucose and insulin tolerance were observed in HFD mice
when compared to ND mice (Figure 3.2d and 3.2e). Taken together, this data indicates
that long-term HFD feeding induces glucose intolerance and insulin resistance in mice
similar to the pre-diabetic phenotype observed in human T2DM patients.
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Figure 3.1 Effect of ND and HFD on body weight and glucose metabolism following
8 weeks of diet treatment
(a) Weekly body weights of mice on ND or HFD for 8 weeks were taken and compared
during dietary treatment (n=7-10 mice per experimental group). (b) Blood glucose levels
were measured following a 16-hour overnight fast after 8 weeks of diet treatment (n=1014 mice per experimental group). (c) Glucose and (d) insulin tolerance tests were
assessed using an intraperitoneal glucose (IPGTT) or insulin (IPITT) injection followed
by statistical analysis of the area under the curve (AUC) (n=7-10 mice per experimental
group). Data were compared using unpaired Student’s t-tests and determined to be
significant at *p<0.05, **p<0.01 vs. ND mice. All data are expressed as means ±SEM.
Black solid circle, ND mice; black solid square, HFD mice.
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Figure 3.2 Effect of ND and HFD on body weight and glucose metabolism following
22 weeks of diet treatment
(a) Biweekly body weights of mice on ND or HFD treatment for 22 weeks (left) and final
body weight of mice at 22 weeks (right) were compared (n=10-17 mice per experimental
group). (b) Blood glucose levels at 22 weeks of diet were measured following a 16-hour
overnight fast. (n=8-10 mice per experimental group). (c) Non-fasted plasma insulin
levels were examined at the end of 22 weeks. (n=5-6 mice per experimental group). (d)
Glucose and (e) insulin tolerance were assessed using an intraperitoneal glucose or
insulin injection followed by statistical analysis of the area under the curve (AUC). (n=610 mice per experimental group). All data are expressed as means ±SEM and compared
using unpaired Student’s t-tests. *p<0.05, **p<0.01, ***p<0.001 vs. ND mice. Black
solid circle, ND mice; black solid square, HFD mice.
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3.2 NAC administration did not change caloric intake during
prevention and intervention treatments
NAC intake in mice fed ND or HFD was not significantly altered in either the 8-week or
22-week diet groups (Figure 3.3). The average NAC intake was similar between ND and
HFD groups (18-18.7 mg/mouse/day) during prevention treatment (Figure 3.3a).
Intervention NAC treatment in ND-fed mice was slightly higher (16 mg/mouse/day)
compared to HFD mice (14 mg/mouse/day) but did not reach statistical significance
(Figure 3.3b). The caloric intake in prevention and intervention groups with diet controls
for 8 or 22 weeks was monitored. No significant change in caloric intake between ND
and ND+pNAC mice and between HFD and HFD+pNAC mice on 8 weeks prevention
treatment was detected, but HFD+pNAC mice had high caloric intake when compared to
ND and ND+pNAC groups (Figure 3.4a). Long term NAC prevention did not alter
caloric intake in both ND+pNAC and HFD+pNAC mice after 22 weeks of prevention
treatment when compared to untreated groups (Figure 3.4b), suggesting that NAC
treatment at long-term administration does not influence caloric intake in either ND and
HFD mice. Caloric intake in intervention NAC treatment groups showed no change
between ND and ND+iNAC or between HFD and HFD+iNAC groups, however,
HFD+iNAC displayed high level caloric intake compared to both ND groups (Figure
3.4c).
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Figure 3.3 NAC intake was similar between diet- and NAC-treated groups in both
prevention and intervention studies.
Average NAC intake for mice undergoing (a) prevention and (b) intervention treatment.
All data were compared using unpaired Student’s t-tests and expressed as means ±SEM.
(n=4-9 mice per experimental group). Blue open circle, ND plus NAC mice; red open
square, HFD plus NAC mice. pNAC, prevention study; iNAC, intervention study.
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Figure 3.4 Caloric intake in diet- and NAC-treated groups in both prevention and
intervention studies.
Average caloric (kcal) intake for mice undergoing a (a) short-term (8 weeks) or (b) longterm (22 weeks) prevention study in ND and HFD mice. (c) Average caloric intake for
ND and HFD mice on intervention NAC treatment at 22 weeks. All data were compared
using a one-way ANOVA with Tukey Post-Hoc and expressed as means ±SEM.
Significance was determined at *p<0.05, **p<0.01. (n=3-13 mice per experimental
group). Black solid circle, ND mice; black solid square, HFD mice; blue open circle, ND
plus NAC mice; red open square, HFD plus NAC mice. pNAC, prevention study; iNAC,
intervention study.
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Figure 3.4
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3.3 Preventative NAC treatment for 8-week HFD did not
affect glucose or insulin tolerance
Antioxidant NAC treatment was administered one week prior to the start of an 8-week
HFD in order to determine whether a reduction in oxidative stress could improve glucose
tolerance. Body weight was monitored weekly (Figure 3.5a). In ND+pNAC mice body
weight was reduced compared to ND, but no significant change in body weight was
observed between HFD and HFD+pNAC mice (Figure 3.5b). Fasted blood glucose levels
were unchanged when comparing between ND and ND+pNAC or HFD and HFD+pNAC
groups (Figure 3.5c). Glucose tolerance tests demonstrated similar response between ND
and ND+pNAC mice as well as between HFD and HFD+pNAC mice. However, HFDpNAC glucose tolerance was significantly worsened compared to ND+pNAC (Figure
3.6a and 6b). Insulin tolerance was not significantly altered, although an improvement at
30 minutes following intra-peritoneal insulin injection was found in HFD+pNAC mice
when compared to HFD mice (Figure 3.6c and 6d).
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Figure 3.5 Body weight and fasted blood glucose levels following NAC prevention
treatment in ND or HFD for 8 weeks.
(a) Weekly body weights were taken for ND, ND+pNAC, HFD, and HFD+pNAC mice
during 8-week prevention treatment. (n=4-9 mice per experimental group). (b) Body
weight and (c) fasted blood glucose levels for 8-week ND, ND+pNAC, HFD, and
HFD+pNAC mice (n=3-9 mice per experimental group). ND and HFD are the same
values from figure 3.1. All data were compared using one-way ANOVA with Tukey
Post-Hoc and expressed as means ±SEM and determined to be significant at *p<0.05,
**p<0.01. Black solid circle, ND mice; black solid square, HFD mice; blue open circle,
ND+pNAC mice; red open square, HFD+pNAC mice. pNAC, prevention study.
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Figure 3.5
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Figure 3.6 NAC prevention treatment for 8 weeks did not restore glucose tolerance
in HFD–fed mice.
(a) IPGTT results from ND, ND+pNAC, HFD, and HFD+pNAC mice during 8-week
experiment and (b) area under curve (AUC) analysis of IPGTT. (n=3-8 mice per
experimental group). (c) IPITT results from ND, ND+pNAC, HFD, and HFD+pNAC
mice during 8-week prevention and (d) AUC analysis of IPITT. (n=4-8 mice per
experimental group). ND and HFD are the same values from figure 3.1. All data were
compared using a one-way ANOVA with Tukey Post-Hoc and expressed as means
±SEM. Significance was determined at *p<0.05, **p<0.01. Black solid circle, ND mice;
black solid square, HFD mice; blue open circle, ND+pNAC mice; red open square,
HFD+pNAC mice. pNAC, prevention study.
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Figure 3.6
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3.4 Preventative NAC treatment affected islet morphology,
beta cell proliferation, and islet PaSCs under ND and
HFD for 8 weeks
Morphological analysis of islet density in the pancreas of ND, HFD and HFD+pNAC
mice was similar, yet ND+pNAC mice showed a

reduction in islet density when

compared to ND islets (Figure 3.7a). There was no significant alteration of islet
architecture between the experimental groups, as determined by the double
immunofluorescence staining of insulin and glucagon (Figure 3.7b). Although HFD mice
showed lower beta and alpha cell mass than that of ND group, similar alpha and beta cell
mass was detected between HFD and HFD+pNAC mice (Figure 3.7c and 7d).
Interestingly reduced beta and alpha cell mass was observed in ND+pNAC mice when
compared to ND mice, although this did not reach statistical significance (Figure 3.7c and
7d). Low sample sizes should be considered when interpreting the changes seen at this
time point. Co-staining of Ki67, a marker of proliferation with insulin positive cells
showed no change in ND+pNAC compared to ND following 8 weeks of diet, but a
reduction of beta cell proliferation in HFD+pNAC compared to HFD samples (Figure
3.8a and 8b). Additionally, mice fed a HFD exhibited an increased intra-islet αSMA+ area
compared to ND, which was significantly decreased using HFD+pNAC (Figure 3.9).
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Figure 3.7 Islet density was significantly decreased in 8-week ND mice on a NAC
prevention treatment.
(a) The number of islets in the pancreas of experimental groups on 8-week pNAC
treatment. (n=3 mice per experimental group).

(b) Representative double

immunofluorescence images for glucagon (green) and insulin (red) staining for ND,
ND+pNAC, HFD and HFD+pNAC treated pancreata. DAPI (blue) was used to label
nuclei. Scale bar, 50 m. Morphometric quantification of (c) beta and (d) alpha cell mass
of all experimental groups. (n=3-5 mice per experimental group). All data are compared
using one-way ANOVA with Tukey Post-Hoc and expressed as means ±SEM. Black
solid circle, ND mice; black solid square, HFD mice; blue open circle, ND+pNAC mice;
red open square, HFD+pNAC mice. pNAC, prevention study.
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Figure 3.7
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Figure 3.8 Beta-cell proliferation in 8-week ND and HFD mice on a NAC prevention
treatment.
(a) Representative double immunofluorescence images for Ki67 (green) and insulin (red)
staining for ND, ND+pNAC, HFD and HFD+pNAC treated pancreata. DAPI, blue. Scale
bar, 50 m. Asterisks represent non-specific blood staining and arrows indicate positive
signaling. (b) Percentage of Ki67 and insulin positive co-stained cells over total insulin
positive cells for beta cell proliferation in the islets of ND mice compared to ND+pNAC
mice and HFD mice compared to HFD+pNAC mice. All data are compared using oneway ANOVA with Tukey Post-Hoc and expressed as means ±SEM (n= 3 mice per
experimental group). Black solid circle, ND mice; black solid square, HFD mice; blue
open circle, ND+pNAC mice; red open square, HFD+pNAC mice. pNAC, prevention
study.
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Figure 3.8
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Figure 3.9 PaSC activation was reduced in HFD mouse islets following preventive
NAC treatment for 8 weeks.
(a) Quantitative analysis of activated PaSCs, labeled by αSMA, in the islets of ND,
ND+pNAC, HFD and HFD+pNAC groups. Representative double immunofluorescence
images for (b) αSMA (green) with insulin (red) with αSMA (green) only images below.
DAPI stained in blue. Scale bar, 50 m. All data are compared using one-way ANOVA
with Tukey Post-Hoc and determined to be significant at *p<0.05. Data expressed as
means ±SEM (n= 3 mice per experimental group). Black solid circle, ND mice; black
solid square, HFD mice; blue open circle, ND+pNAC mice; red open square,
HFD+pNAC mice. pNAC, prevention study.
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Figure 3.9
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3.5 Preventative NAC treatment for a 22-week HFD
improved mouse glucose and insulin tolerance
Due to the early nature of the 8-week time point, which did not demonstrate an
improvement with short-term NAC treatment, the NAC prevention study was extended
throughout 22 weeks of HFD feeding to determine whether significant improvements
could be found with a longer treatment and when compared to a progressively glucose
intolerant phenotype. Bi-weekly body weight was monitored for 22 weeks of diet and
showed that NAC treatment reduced body weight in both ND+pNAC and HFD+pNAC
compared to ND and HFD mice, respectively (Figure 3.10a and b). ND+pNAC mice
showed no significant changes in fasting blood glucose, glucose tolerance, or insulin
resistance when compared to ND mice (Figure 3.10 and 3.11). Preventive NAC treatment
in HFD mice (HFD+pNAC) displayed lower fasted blood glucose level and circulating
plasma insulin levels compared to HFD mice (Figure 3.10c,d). Furthermore, HFD+pNAC
treatment was able to significantly improve glucose tolerance and insulin tolerance when
compared to HFD mice (Figure 3.11). At the islet level, improvements in beta cell mass
(Figure 3.12b,c) and intra-islet αSMA positive area were observed (Figure 3.12).
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Figure 3.10 Effect of preventative NAC treatment on body weight and fasted blood
glucose level following 22 weeks of diet.
(a) Bi-weekly body weights were measured in ND, ND+pNAC, HFD and HFD+pNAC
mice during 22-week treatment. (b) Body weight and (c) fasted blood glucose levels at
22-week in ND, ND+pNAC, HFD, and HFD+pNAC treated mice. (n=3-17 mice per
experimental group). (d) Non-fasted plasma insulin levels were examined at the end of
the experiments (n=3-6 mice per experimental group). ND and HFD are the same values
from figure 3.2. All data were compared using a one-way ANOVA with Tukey Post-Hoc
and expressed as means ±SEM. Significance was determined at *p<0.05, **p<0.01.
Black solid circle, ND mice; black solid square, HFD mice; blue open circle, ND+pNAC
mice; red open square, HFD+pNAC mice. pNAC, prevention study.
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Figure 3.10
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Figure 3.11 NAC prevention treatment for 22 weeks restored glucose tolerance in
HFD–fed mice.
(a) IPGTT from ND, ND+pNAC, HFD, and HFD+pNAC mice after 22 weeks of
treatment and (b) area under curve (AUC) analysis of IPGTT. (n=7-10 mice per
experimental group). (c) IPITT from ND, ND+pNAC, HFD, and HFD+pNAC after 22week treatment and (d) AUC analysis of IPITT. (n=6-9 mice per experimental group).
ND and HFD are the same values from figure 3.2. All data were compared using a oneway ANOVA with Tukey Post-Hoc and expressed as means ±SEM. Significance was
determined at *p<0.05, **p<0.01. Black solid circle, ND mice; black solid square, HFD
mice; blue open circle, ND+pNAC mice; red open square, HFD+pNAC mice. pNAC,
prevention study.
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Figure 3.11
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Figure 3.12 Long term NAC prevention treatment for 22 weeks normalizes beta cell
mass and reduces intra-islet αSMA staining.
(a) Islet density in the pancreas of experimental groups at 22-week pNAC treatment.
(n=3-5 mice per experimental group). (b) Representative double immunofluorescence
images for glucagon (green) and insulin (red) staining for ND, ND+pNAC, HFD and
HFD+pNAC treated pancreata. DAPI (blue) was used to label nuclei. Scale bar, 50 m.
(c) Morphometric quantification of beta cell mass of all experimental groups. (n=3-6
mice per experimental group). (d) Representative double immunofluorescence images for
αSMA (green) and insulin (red) for ND, ND+pNAC, HFD and HFD+pNAC treated
pancreata. DAPI (blue) was used to label nuclei. Scale bar, 50 m. All data were
compared using a one-way ANOVA with Tukey Post-Hoc and expressed as means
±SEM. Significance was determined at *p<0.05, **p<0.01. Black solid circle, ND mice;
black solid square, HFD mice; blue open circle, ND+pNAC mice; red open square,
HFD+pNAC mice. pNAC, prevention study.
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Figure 3.12
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3.6 Intervention NAC treatment did not improve HFDinduced glucose intolerance
Mice under HFD for 22 weeks demonstrated a progressive T2DM-like phenotype when
compared to 8-week HFD mice. After 12 weeks of ND and HFD, mice received NAC as
an intervention treatment (iNAC) until 22 weeks following diet. In ND+iNAC mice, a
significant reduction in body weight was associated with lower fasting blood glucose
when compared to ND mice, but no change to non-fasted plasma insulin levels was
detected between the two groups (Figure 3.13). Similar glucose and insulin tolerance
were found between ND and ND+iNAC mice (Figure 3.14). There was no difference of
body weight and fasted blood glucose level observed between HFD and HFD+iNAC
mice, but non-fasted plasma insulin level in HFD+iNAC mice was significantly lower
than that of HFD mice (Figure 3.13). It was also noted that there were no improvements
in glucose tolerance in the HFD+iNAC group compared to HFD, and HFD+iNAC
maintained significantly worsened glucose tolerance compared to ND. While insulin
tolerance was not significantly improved in HFD+iNAC compared to HFD, significant
change between HFD+iNAC and ND groups was lost (Figure 3.14).
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Figure 3.13 Effect of NAC intervention treatment on body weight, blood glucose,
and plasma insulin levels following 22 weeks of diet.
(a) Biweekly body weights were measured from ND, ND+iNAC, HFD and HFD+iNAC
mice during the 22 weeks of treatment. (n=7-17 mice per experimental group). (b) Body
weight, (c) fasted blood glucose levels, and (d) non-fasted plasma insulin levels were
measured at 22 weeks of diet in ND, ND+iNAC, HFD, and HFD+iNAC mice. (n=6-10
mice per experimental group). ND and HFD are the same values from figure 3.2. All data
were compared using a one-way ANOVA with Tukey Post-Hoc and expressed as means
±SEM. Significance was determined at *p<0.05, **p<0.01. Black solid circle, ND mice;
black solid square, HFD mice; blue open circle, ND+iNAC mice; red open square,
HFD+iNAC mice. iNAC, intervention study.
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Figure 3.13
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Figure 3.14 NAC intervention treatment for 22 weeks did not restore glucose
tolerance in HFD–fed mice.
(a) IPGTT from ND, ND+iNAC, HFD, and HFD+iNAC mice after 22 weeks and (b) area
under curve (AUC) analysis of IPGTT. (n=8-11 mice per experimental group). (c) IPITT
from ND, ND+iNAC, HFD, and HFD+iNAC mice after 22 weeks and (d) AUC analysis
of IPITT. (n=5-8 mice per experimental group). ND and HFD are the same values from
figure 3.2. All data were compared using a one-way ANOVA with Tukey Post-Hoc and
expressed as means ±SEM. Significance was determined at *p<0.05, **p<0.01. Black
solid circle, ND mice; black solid square, HFD mice; blue open circle, ND+iNAC mice;
red open square, HFD+iNAC mice. iNAC, intervention study.
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Figure 3.14
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3.7 Intervention NAC treatment affected islet morphology in
22-week ND and HFD mice
Morphological analysis for islet density showed no significantly altered islet number in
the pancreatic sections between experimental groups (Figure 3.15a). Increased beta cell
mass was found in HFD mice compared to ND mice after 22 weeks study with similar
alpha cell mass observed (Figure 3.15b and 15c). Similar beta and alpha cell mass were
observed between the ND and ND+iNAC mouse pancreas. However, HFD-induced
increased beta cell mass was reduced in HFD+iNAC mice (Figure 3.15b and 15c).
However, this did not reach statistical significance as variability was noted between HFD
and HFD+iNAC groups.
To verify whether reduced beta cell mass was associated with the beta cell size and
number, individual beta cell size and total number of beta cells in the islets was
measured. Significantly larger beta cell size with lower beta cell number in the islets was
found in the HFD mice compared to ND mice, with no change in the size and the number
between ND and ND+iNAC groups (Figure 3.16). However, HFD+iNAC mice displayed
significantly smaller beta cell size and higher beta cell number in islets when compared to
HFD mice (Figure 3.16). Both beta cell size and number in HFD+iNAC mice were
similar to ND and ND+iNAC groups, suggesting HFD mice under intervention NAC
treatment could restore a normal beta cell phenotype seen in ND mice.
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Figure 3.15 Intervention NAC treatment affected islet morphology in ND and HFD
at 22 weeks.
(a) The number of islets in the pancreas of all experimental groups at 22 weeks of diet
with NAC intervention. (n=3-5 mice per experimental group). Morphometric
quantification of (b) beta and (c) alpha cell mass of all experimental groups. (n=3-6 mice
per experimental group). ND and HFD beta cell mass and islet density are the same
values compared in figure 3.12. All data are compared using one-way ANOVA with
Tukey Post-Hoc and expressed as means ±SEM. Black solid circle, ND mice; black solid
square, HFD mice; blue open circle, ND+iNAC mice; red open square, HFD+iNAC
mice. iNAC, intervention study.
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Figure 3.15
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Figure 3.16 Intervention NAC treatment affected beta cell size and number in ND
and HFD at 22 weeks.
(a) Average beta cell size and (b) number of beta cells in the insulin+ area of ND,
ND+iNAC, HFD and HFD+iNAC mice at 22 weeks of diet with NAC intervention.
(n=4-6 mice per experimental group). (c) Representative double immunofluorescence
images for glucagon (green) and insulin (red) staining for ND, ND+iNAC, HFD and
HFD+iNAC treated pancreata. DAPI, blue. Scale bar, 50 m. All data were compared
using a one-way ANOVA with Tukey Post-Hoc and expressed as means ±SEM.
Significance was determined at *p<0.05, **p<0.01. Black solid circle, ND mice; black
solid square, HFD mice; blue open circle, ND+iNAC mice; red open square, HFD+iNAC
mice. iNAC, intervention study.
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Figure 3.16
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Figure 3.17 Beta-cell proliferation in 22-week ND and HFD mice on a NAC
intervention treatment.
(a) Representative double immunofluorescence images of Ki67 (green) and insulin (red)
staining of ND, ND+iNAC, HFD and HFD+iNAC treated pancreata. DAPI, blue. Scale
bar, 50 m. Asterisks represent non-specific blood staining and arrows indicate positive
signaling. (b) Percentage of Ki67 and insulin positive co-stained cells over total insulin
positive cells to determine beta cell proliferation in the islets of ND mice compared to
ND+iNAC mice and HFD mice compared to HFD+iNAC mice. All data were compared
using a one-way ANOVA with Tukey Post-Hoc are expressed as means ±SEM (n= 3-4
mice per experimental group). Black solid circle, ND mice; black solid square, HFD
mice; blue open circle, ND+pNAC mice; red open square, HFD+pNAC mice. iNAC,
intervention study.
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Figure 3.17
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3.8 Intervention NAC treatment restored nuclear PDX-1
expression and lowered intra-islet PaSC activation
To examine whether NAC intervention treatment improved beta cell PDX-1 expression,
double immunostaining for PDX-1 with insulin was performed (Figure 3.18a). The
nuclear PDX-1 localization in HFD beta cells was significantly reduced compared to ND
beta cells after 22 weeks of diet (Figure 3.18b). There was no change in nuclear PDX-1
localization between ND and ND+iNAC groups, but HFD+iNAC beta cells significantly
improved of nuclear PDX-1 localization compared to HFD beta cells (Figure 3.18b).
Furthermore, the PaSC activation marker αSMA was increased in islets of HFD mice
compared to ND mice (Figure 3.19a), as determined by double immunofluorescence
staining for αSMA and insulin (Figure 3.19b). Similar activation levels of PaSCs were
observed between ND and ND+iNAC groups, but PaSCs populations were reduced in
HFD+iNAC islets when compared to HFD (Figure 3.19c).
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Figure 3.18 Intervention NAC treatment affected beta cell PDX-1 expression under
ND and HFD at 22 weeks.
(a) Representative double immunofluorescence images for PDX-1 (green) and insulin
(red) staining for ND, ND+iNAC, HFD and HFD+iNAC mouse pancreata with PDX-1
(green) images only below each representative. DAPI, blue. Scale bar, 50 m. (b) The
percent of nuclear PDX-1 staining found in the beta cells of ND, ND+iNAC, HFD and
HFD+iNAC mice. (n=4 mice per experimental group). DAPI, blue. Scale bar, 50 m. All
data were compared using a one-way ANOVA with Tukey Post-Hoc and expressed as
means ±SEM. Significance was determined at *p<0.05, **p<0.01. Black solid circle, ND
mice; black solid square, HFD mice; blue open circle, ND+iNAC mice; red open square,
HFD+iNAC mice. iNAC, intervention study.
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Figure 3.18
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Figure 3.19 Intervention NAC treatment affected the islet PaSC population under
ND and HFD at 22 weeks.
(a) Quantitative analysis of activated PaSCs, labeled by αSMA, in the islets of ND,
ND+iNAC,

HFD

and

HFD+iNAC

groups.

(b)

Representative

double

immunofluorescence images for αSMA (green) with insulin (red) (n=4-5 mice per
experimental group) with αSMA (green) channels alone beneath each representative and
DAPI, blue. Scale bar, 50 m. (n=3 mice per experimental group). All data were
compared using a one-way ANOVA with Tukey Post-Hoc and expressed as means
±SEM. Black solid circle, ND mice; black solid square, HFD mice; blue open circle,
ND+iNAC mice; red open square, HFD+iNAC mice. iNAC, intervention study.
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Figure 3.19
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Chapter 4

4

Discussion

The objective of this study was to determine the effects of NAC treatment on beta cell
function under normal or high fat diet condition when administered as either a
preventative or intervention treatment. It was hypothesized that preventing HFD-induced
beta cell dysfunction using NAC will improve beta cell function and reduce the activation
of the islet PaSC (αSMA+) population. B6N mice were fed a short-term (8 weeks) or
long-term (22 weeks) 60% HFD to determine the onset of glucose intolerance before
application of preventative NAC (throughout 8- or 22-week HFD) or intervention NAC
(beginning at week 12 of a 22-week HFD) treatments. The findings from this thesis
demonstrated that an 8-week preventative NAC treatment did not induce metabolic and
histologic effects on glucose tolerance and islet morphology but did reduce the presence
of αSMA+ cells within HFD islets. Long-term NAC prevention treatment improved
glucose tolerance and insulin sensitivity by reducing weight gain in HFD mice. However,
NAC intervention prevented compensatory beta cell hypertrophy and restored PDX-1
localization but did not restore glucose tolerance in HFD mice. The aims from this study
helped elucidate the effectiveness of NAC on metabolic outcomes when applied at
different times during T2DM progression and the effects NAC exerts on the beta cells at
these time points during a prevention or intervention study.

4.1 What duration of HFD is required to induce glucose
intolerance and insulin resistance?
B6N mice are commonly used as DIO rodent models of T2DM as they progress through
a series of stages similar to what is found in humans (Ingvorsen, Karp, & Lelliott, 2017).
Following a 60% HFD for 8 weeks, B6N mice displayed a significant increase in body
weight accompanied by glucose intolerance with no significant change to fasting blood
glucose (FBG) and insulin tolerance. This is consistent with the findings of Mosser et al.
that suggest that changes in glucose metabolism are prior to the existence of insulin
resistance in diet-induced obese rodent models (Mosser et al., 2015; Nicholson et al.,
2010). In human T2DM, an intermediate stage of prediabetes is described with the
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presence of glucose intolerance and/or elevated FBG that are not accompanied by insulin
resistance or severe symptoms such as polyuria and polydipsia (Assoc, 2011). An 8-week
HFD treatment appears to produce a similar stage of early prediabetes in B6N mice due
to the presence of glucose intolerance and lack of additional T2DM signs.
A more severe phenotype emerged after 22-weeks of HFD treatment, which was
confirmed by both severely impaired insulin tolerance as well as increased levels of
circulating plasma insulin. This was also supported by picrosirius red staining of liver
sections in HFD mice compared to ND mice, wherein increased steatosis can be
suggestive of impaired organ function (Appendix C) and involved in the progression of
insulin resistance (Falach-Malik et al., 2016). Glucose tolerance was worsened at this
time when compared to mice on 8 weeks of HFD, and the increase in final body weight
of HFD mice compared to ND mice was more pronounced. After 8-weeks of HFD
treatment mice presented characteristics of prediabetes but had not progressed to signs of
insulin deficiency, which suggested that at 22 weeks HFD mice were more severely
glucose impaired than HFD mice at week 8 but had not progressed to uncontrolled
hyperglycemic levels (Assoc, 2011; Fisher-Wellman et al., 2016; Rendina-Ruedy et al.,
2015). This is consistent with the classification of the DIO B6N mouse model as a model
of prediabetes (Rendina-Ruedy et al., 2015).

4.2 Does administration of NAC prior to the beginning of
HFD prevent glucose intolerance?
While glucose intolerance was evident at week 8 of HFD in B6N mice, it was not
prevented with NAC administration in HFD+pNAC in 8 weeks mice. These mice
displayed attenuated weight gain starting at week 6 of HFD compared to HFD only mice
and displayed a slight improvement in insulin sensitivity from 0-30 minutes postinjection. However, final body weight and insulin tolerance after 8 weeks of diet in
HFD+pNAC and HFD mice were not significant. While other studies have found a
significant improvement in glucose tolerance in B6J mice following a 9-week HFD with
400 mg/kg/day of NAC in drinking water, these mice also had a significant reduction in
body weight that was unrelated to alterations in food consumption (Falach-Malik et al.,
2016). It has long been known that body weight reduction is able to improve glucose

72

tolerance and insulin sensitivity (Hamman et al., 2006). Mice of a B6J background gained
weight at different rates than those with a B6N background (Fisher-Wellman et al., 2016;
Nicholson et al., 2010) which may account for changes in the length of time required to
achieve weight loss for our B6N mice treated with NAC. It appears that weight loss
independent of reduced food consumption played a role in the outcomes associated with
NAC. Alterations may be occurring with insulin sensitivity in 8-week prevention
HFD+pNAC mice but may not have reached significance as significant changes to HFD
mice compared to ND mice had not yet developed. Therefore, the continuation of NAC
administration with diet for a longer time period may have produced more conclusive
improvements to glucose tolerance.
Previous studies have suggested that longer treatment periods with NAC increased its
effectiveness and induced weight loss in rodents (Shen et al., 2019). To determine
whether improvements could be found following a long-term preventative treatment with
NAC, mice were treated with pNAC for a duration of 22 weeks. Following HFD+pNAC
for 22 weeks, these mice displayed significantly improved glucose tolerance and
improved FBG compared to 22-week HFD mice. Significantly improved insulin
tolerance as well as reduced circulating plasma insulin levels were also noted. Studies
involving NAC administration often demonstrate increased effectiveness when decreased
body weight is independent of reduced caloric intake (Falach-Malik et al., 2016; Novelli
et al., 2009; Shen et al., 2019). Consistent with these findings, the increased effectiveness
of NAC on metabolic outcomes found in HFD+pNAC mice following during a 22-week
HFD were associated with a reduction in weight gain, independent of reduced caloric
intake. While caloric intake is not responsible for alterations in weight gain, Novelli et al.
and Shen et al. have suggested increased motor activity and changes to metabolic activity
levels which may account for the changes to weight gain on HFD+pNAC (Novelli et al.,
2009; Shen et al., 2019).
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4.3 Does preventative NAC administration enhance beta
cell mass during early compensation in HFD mice?
During oxidative stress, beta cells are known to increase beta cell mass predominantly
through proliferation, which is one of the first changes made in the beta cell population in
response to HFD (Mosser et al., 2015). When oxidative stress is reduced through
antioxidant such as NAC, it has been suggested that beta cells decrease proliferation
(Alfar et al., 2017). Mice fed HFD for 8 weeks did not display increased beta cell mass
compared to ND but displayed increasing proliferation rates. However, beta cell mass in
appeared relatively unchanged in HFD+pNAC mice compared to HFD-fed mice for 8
weeks. Interestingly, ND+pNAC mice displayed a trend towards decreased beta cell mass
compared to ND mice following 8-weeks of diet, which was accompanied by a decrease
in alpha cell mass. This may be due to a reduction in the number of islets found per mm².
Alfar et al. have found a physiological role of H2O2 in beta cell proliferation, which is
inhibited by antioxidants such as NAC (Alfar et al., 2017) and may account for the
reduction in ND+pNAC beta cell mass during a potential time of physiological
expansion.
The 8-week time point has shown to be an early time point in T2DM progression, leading
to the evaluation of beta cell mass following NAC prevention 1 week prior to and during
22 weeks of diet. Following an increase in beta cell mass in HFD islets compared to ND,
long term NAC prevention did not alter beta cell mass in long term ND+pNAC samples
but normalized beta cell mass in HFD+pNAC pancreata. These changes were unrelated to
changes in total islet number. Taken with the improved metabolic testing, long-term NAC
prevention may be protecting the beta cells from markers related to over-compensatory
related dysfunction seen at this time point. More studies on the cause behind a lack of
HFD induced beta cell mass increase following long term NAC prevention are warranted
to determine whether the lack of increase is due to alterations in size or proliferation
rates. Additionally, whether long-term pNAC is effective at not only restoring normal
beta cell mass, but also markers of function will be examined in future studies.
Interestingly, a large reduction in αSMA+ area indicative of PaSC activation was found in
HFD+pNAC compared to HFD islets at 22 weeks of diet. A lack of PaSC activation and
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associated growth factors could be partially responsible for the lack of increased beta cell
mass at this time point.

4.4 Is preventative NAC treatment able to inhibit the
activation of PaSCs in vivo?
Active PaSCs are identified in vivo primarily through the marker αSMA. Intra-islet
immunofluorescence staining showed an increase in αSMA+ cell area in the islets of 8week HFD mice compared to ND mice and this was reduced in HFD+pNAC mice. Intraislet αSMA+ area in the islets of 22-week HFD mice was also increased compared to ND
mice, which was greatly reduced by long term NAC prevention treatment, suggesting that
once NAC is administered it is able to prevent as well as maintain low levels of intra-islet
PaSC activation. Whether a lack of PaSC associated growth factors is partially
responsible for the decreased beta cell mass found in 22-week HFD+pNAC mice has yet
to be determined and will be examined in future studies.
Antioxidants such as NAC have been shown to decrease PaSC activation (Asaumi et al.,
2007; Jesnowski et al., 2005) in vitro in primary cultured PaSCs, while antioxidants such
as pirfenidone have been shown to reduce intra-islet activation in vivo (Lee et al., 2017).
Whether the inhibition of PaSC activation prior to and during HFD contributes to
alterations in beta cell function in a beneficial or negative manner has yet to be
elucidated.

4.5 Does administration of NAC during HFD improve
glucose tolerance?
A severe prediabetic state, including severely impaired glucose tolerance found following
22 weeks of HFD, was not significantly improved with HFD+iNAC treatment.
Significantly improved circulating plasma insulin level suggestive of improved
hyperinsulinemia was found compared to HFD. However, only a mild improvement in
insulin tolerance was observed through a lack of significant improvement between HFD
and HFD+iNAC groups, but the loss of significant difference between ND and
HFD+iNAC found following intervention treatment. Improved liver steatosis in
HFD+iNAC mice compared to HFD mice were also noted, suggesting improvements that
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may have affected peripheral insulin resistance (Appendix C). Interestingly, glucose
tolerance from 0-60 minutes was not improved, while glucose levels in HFD+iNAC mice
appeared to return closer to baseline levels compared to HFD mice at 120 minutes. It has
been suggested that the first phase of insulin release is sometimes more severely
impacted by T2DM progression (Pedersen et al., 2019), which leaves the possibility that
the second phase of insulin release may be improved first during iNAC treatment while
the first, more heavily impacted phase may require more treatment time. As with pNAC
treatment for 8 weeks, iNAC mice did not display significantly reduced final body weight
but showed a pattern of mild body weight gain attenuation following the start of NAC
treatment. This was not related to caloric intake, in which there was no reduction. B6J
mice have been shown to display significantly improved insulin resistance and glucose
tolerance when put on NAC intervention treatment beginning at month 3 during a 6month HFD. While these mice did not lose a significant amount of body weight at 6
months, the study showed improved glucose tolerance and insulin tolerance in mice given
NAC from 1-6 months of HFD compared to 3-6 months of HFD, supporting the
importance of a long-term treatment time in the effectiveness of NAC (Shen et al., 2019).
Additionally, it is important to note the changes in the background of the mice in which
the study was conducted. B6N and B6J mice gain weight at different rates, and motor
activity is affected differently in each strain which may account for the differences in rate
of weight gain (Nicholson et al., 2010). Mice in the current study appear to be at the
beginning of metabolic improvements, and it is conceivable that the extra month of NAC
treatment afforded to the HFD+iNAC mice in the Shen et al. study would allow for
improvements in metabolic outcomes.
In ND+iNAC mice, a significant reduction in final body weight was noted that was
associated with a reduction in FBG, while caloric intake was unchanged. Studies have
suggested that NAC is able to alter metabolic activity levels to cause weight loss that is
not caused by a decrease in caloric intake (Novelli et al., 2009; Shen et al., 2019), which
may account for alterations to ND metabolic outcomes following treatment with NAC.
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4.6 Does administration of NAC during HFD prevent later
stage beta cell failure associated with T2DM
progression?
Progression of beta cells through T2DM-like DIO involves compensation, dysfunction,
and eventual failure. Compensation is characterized by an increase in mass due to
increased proliferation and/or size (Alfar et al., 2017; Granot et al., 2009) which
contributes to hyperinsulinemia. Following a 22-week HFD, an increase in beta cell mass
associated with the compensatory stage was found when compared to ND mice. Beta
cells in the HFD environment increased in size and proliferation rates compared to ND in
order to increase mass as well as insulin production. It was found that HFD+iNAC beta
cell size was significantly smaller than in HFD mice, reflecting a size more comparable
to that found in ND mice. HFD+iNAC normalized overall beta cell mass, an
improvement compared to the increased beta cell mass found in HFD. These changes
were unrelated to changes in beta cell proliferation rates. However, with the current lack
of change in proliferation rates, it is not clear whether a change of mass at this time point
is attenuated or reversed. While HFD mice display markers of compensation in response
to HFD, it appears that HFD+iNAC reduces mechanisms indicative of overcompensation leading to hyperinsulinemia.
In addition to markers of compensation, HFD beta cells at 22 weeks displayed signs of
dysfunction. Nuclear PDX-1 localization is responsible for inducing insulin transcription,
thereby maintaining overall insulin levels within the beta cells and is indicative of beta
cell identity (Kawamori et al., 2003; Ma et al., 2016). A significant reduction in nuclear
PDX-1 localization was found in the beta cells of HFD mice compared to ND mice and is
a classic sign of dysfunction related to oxidative stress (Kawamori et al., 2003). NAC has
been shown to improve nuclear PDX-1 mRNA levels in islets isolated from ZDF rats
(Tanaka et al., 1999). Consistent with these findings HFD+iNAC beta cells displayed
significantly improved nuclear PDX-1 localization compared to HFD islets, suggesting
either a reversed or delayed dysfunctional state in relation to insulin production.
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4.7 Is intervention NAC treatment able to reduce PaSC
activation during HFD in vivo?
n Increased in intra-islet αSMA+ staining in 22-week HFD islets compared to ND islets
was reduced in HFD+iNAC islets compared to HFD, suggesting a reduction in PaSC
activation. Once PaSCs are initially activated by factors such as ROS, they continue
activation through autocrine and paracrine factors (Saito et al., 2012). While difficult to
reduce or reverse PaSC activation, it has been found that NAC is capable of deactivating
PaSCs in vitro under the correct environmental conditions (Jesnowski et al., 2005).
PaSCs are capable of producing growth factors and hormones (Ryu et al., 2013) that may
be involved in the HFD-induced increase of beta cell mass that is absent following iNAC
treatment at this time point. Whether reducing intra-islet PaSC activation has a positive or
negative influence on this stage of compensation has yet to be determined.

4.8 Limitations of the Study and Methodology
The DIO B6N model has many benefits, including less genetic drift and the presence of
the wildtype Nnt gene, which is also present in humans (Fisher-Wellman et al., 2016).
However, this model is generally accepted as a prediabetic model in T2DM progression
(Rendina-Ruedy et al., 2015), which does not typically progress to overt diabetes
characterized by weight loss and loss of beta cell mass. Without such markers of
dysfunction, it is difficult to determine the effects of NAC on attenuation versus
prevention on dysfunction as the model likely will not progress to this severe T2DM state
(King, 2012). However, finding a DIO model that progresses past prediabetes without the
presence of genetic manipulation is challenging and would introduce a confounding
variable in the assessment of the effects of an antioxidant on beta cell compensation and
dysfunction. While wild type HFD DIO mouse models are accepted models displaying
the importance of oxidative stress in the beginning of and during T2DM progression, the
use of alternative mouse models may be necessary to more effectively determine the late
stage effects of NAC treatment on beta cell function.
Studies suggest alterations in motor activity or genes related to motor activity can lead to
reduced body weight without reduced caloric intake (Novelli et al., 2009; Shen et al.,
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2019). While it was determined that a reduction of caloric intake was not the cause of
reduced body weight in ND mice treated with NAC in the short-term prevention and
intervention studies, motor studies and genetic analysis were not performed to determine
whether alterations in motor activity was the cause of weight gain attenuation. It is
important to note no stimuli were added in the cages that could differentially impact
exercise levels compared to other studies and no caloric intake alterations were found in
ND compared to ND+NAC mice, suggesting that motor activity and related genes should
be examined in B6N mice and compared to the changes found in B6J mice to determine
whether these are the definitive causes of weight gain attenuation.
A major limitation of assessing PaSC activation is a lack of the existence of specific
markers to determine active PaSCs from intra-islet pericytes. However, pericytes and
PaSCs likely belong to the same family of mesenchymal-like cells that exist within the
islet, with the difference between the two types being that pericytes have been shown to
exist surrounding vessels (Erkan et al., 2012). Additionally, Hayden et al. have suggested
that pericytes may be able to differentiate into PaSCs (Hayden et al., 2007). However,
one suggested marker that is not shared between pericytes and PaSCs may be Nkx3.2
(Sasson et al., 2016). With this topic still largely under debate, αSMA+ positive cells are
considered suggestive of PaSC activation for the purposes of this study. Lastly, when
staining for αSMA+ area, a mouse derived antibody was used on mouse tissue which
leaves the opportunity for the anti-mouse secondaries to bind to non-specific antigens
within the tissue resulting in high background. When quantifying, only positive αSMA+
area with distinct cytoplasmic staining around a nucleus was counted. However, as mouse
on mouse staining does result in higher background either a rabbit derived αSMA
antibody or a mouse on mouse kit should be considered in the future.
Lastly, large variability due to low sample sizes was observed in assays of 8-week NAC
prevention samples. This sample size will be increased in future studies.

4.9 Conclusion and Future Direction
In summary, this study suggests that NAC is most effective on overall metabolic
outcomes when administered for a treatment period long enough to induce significant
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weight gain attenuation. While 8 weeks appears to be too early to see the full effect of
prediabetes induced by HFD, pNAC at this time point can improve beta cell proliferation
rates as well as decrease intra-islet αSMA+ staining. Following intervention treatment,
NAC partially protects beta cells from signs of overcompensation as well as dysfunction
that are associated with a long-term HFD, while reducing intra-islet αSMA+ staining.
To determine whether dysfunction at later stages was attenuated, prevented, or reversed
markers for apoptosis, such as caspase-3 (Porter & Jänicke, 1999) must be examined in
the in vivo embedded samples. Additionally, a mouse model reliant on oxidative stress
driving T2DM progression to dysfunction should be utilized in order to determine the
effective NAC at protecting beta cell viability. One such model that must be considered is
the streptozotocin (STZ)/HFD rat model. T2DM may be induced in this model with
multiple, smaller doses of STZ compared to the dosage required to induce T1DM. STZ is
a beta cell toxin, and when paired with HFD to induce hyperinsulinemia, insulin
resistance and hyperglycemia allow for both early and late stages of T2DM to be
examined as opposed to the prediabetic model produced by HFD alone (Skovsø, 2014).
Using the STZ/HFD model to induce both early and late stages of T2DM and applying a
long-term prevention or intervention NAC treatment could shed light on whether the
effects of NAC are causing attenuation or reversal of dysfunction in the beta cells.
While NAC is a well-known antioxidant, it is important to determine how effective the
drug is at reducing levels of oxidative stress within the islets at the various treatment
times and at the specific dosages used within the study. While NAC is likely more
effective at the higher dosage because it reduces oxidative stress more so than a lower
dosage, this must be confirmed using immunohistochemical markers of intra-islet ROS
levels such as 8-hydroxy-2’-deoxyguanosine (8-OHdG) (Miki et al., 2018).
Lastly, while NAC appears to be protecting beta cell function from DIO induced
dysfunction, how it is exerting its effects has yet to be determined. Whether NAC is
affecting beta cell function directly or indirectly is a long-standing question. This study
demonstrates a reduction of intra-islet PaSC activation, which can be related to
alterations in beta cell mass and function at various points throughout T2DM progression.
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Whether NAC exerts a direct effect, an indirect effect, or potentially both through the
subsequent effects of PaSC reduction have yet to be determined. To help determine
whether NAC exerts primarily direct or indirect effects, administration of NAC on islets
isolated from ND and HFD mice following 22 weeks of diet to assess its direct
antioxidant capacity compared to glutathione administration to assess indirect antioxidant
effects should be conducted. Additionally, a similar assay should be conducted on
isolated PaSCs from 22-week ND or HFD mice to determine whether NAC has an
indirect or direct effect on PaSC activation levels. Additionally, while a co-culture of
isolated islets and PaSCs have shown to have an overall negative effect on insulin
production within the beta cells (Zang et al., 2015), it is not known if the reduction of
PaSC activation plays positive or negative roles in beta cell viability at the various stages,
and how those effects may be employed provide a future avenue for NAC and beta cell
related studies. To potentially assess the effects of PaSCs on beta cell viability, PaSCs
isolated from NAC treated or non-treated mice following an intervention or long-term
prevention study should be either directly cultured with islets isolated from age-matched
mice or cultured via a transwell system. It is difficult to study PaSCs in vitro due to their
ability to become activated by the culture plate and process, but it has been suggested that
this activation may be attenuated using Matrigel (Jesnowski et al., 2005). Utilizing these
methods could help determine the role of PaSCs on beta cell function at various time
points during T2DM progression in a diet-induced obesity model.
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Appendices
Appendix A: 2017-093 Animal Use Protocol (AUP)

A
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Appendix B: Biosafety Approval Form
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Appendix C: Picrosirius red staining of iNAC liver samples

22-week ND, HFD, ND+iNAC, and HFD+iNAC treated samples were stained for
picrosirius red to detect fibrosis and steatosis. Scale bar, 50µm.
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Appendix D: IF Staining Controls for αSMA

4% PFA fixed and paraffin embedded adult mouse pancreatic tissue was stained for: antiαSMA antibody only in (-) control 1 or FITC-conjugated anti-mouse and TRITCconjugated anti-rabbit IgG only in (-) control 2. Nuclei were stained for DAPI. Scale bar,
50µm. Asterisks indicate non-specific staining of blood cells, also demonstrated by
overlap in FITC and TRITC in composite images.
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